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Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.006More than 15 years ago, Nico Pijls, from Eindhoven, the
Netherlands, conceived, and, along with Bernard De
Bruyne from Aalst, Belgium and others, developed and
tested the fractional flow reserve (FFR) concept (1–3). They
are to be credited for one of the most important advances in
the diagnosis and treatment of coronary artery disease in the
percutaneous coronary intervention (PCI) era. The current
paradigm of FFR revolutionized coronary physiology and
translated directly to the practical in-lab functional assess-
ment of coronary stenosis in patients before and during
PCI.
See page 1392
The working theory of FFR is derived from the fact that
coronary pressure is linearly related to flow only if the
coronary microcirculatory resistance is constant and mini-
mal. FFR is thus computed from the ratio of absolute
translesional pressures measured during pharmacologically
induced (usually adenosine) hyperemia required to achieve
the necessary resistance condition. The validation studies
and the studies of associated beneficial clinical outcomes
have finally placed FFR on strong bedrock for daily use in
the cath lab (4–7).
However, despite demonstrating better outcomes with
FFR guidance for PCI treatment decisions (6,7) and the
recent FAME (Fractional Flow Reserve Versus Angiogra-
phy for Multivessel Evaluation) economic study showing
the lower cost of achieving such outcomes (8), the use of
FFR in the interventional community at large is 10% of
PCI procedures performed in the absence of appropriate
clinical evidence and at times in contravention to guideline
recommendations (9,10). Why is the use of FFR less than
what one would expect for such a strongly supported in-lab
measure of ischemia, a measurement that is particularly
helpful, if not critical, when uncertainty exists regarding the
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discussed previously (11), involve concerns regarding the
perceived increased procedure time and cost, physician
reimbursement, uncertainty about the technique or data,
and the cumbersome requirement of adenosine with com-
plaints about dose, route of administration, femoral venous
access, and achievement of maximal hyperemia.
Motivated by both science and practicality, Sen et al. (12)
now present a novel concept, the instantaneous wave-free
pressure ratio (iFR), using and expanding on the tenets of
FFR. iFR, an index of stenosis severity, is based on the
instantaneous ratio of translesional pressures acquired dur-
ing a specific period of diastole in which the coronary
microcirculatory resistance is constant and minimal, fulfill-
ing the FFR resistance criteria without the need for aden-
osine hyperemia.
In their most recent and perhaps the most clinically
relevant work, Sen et al. (12) identified through their earlier
studies of coronary wave–intensity analysis (13) a period of
diastole in which an equilibrium or balance between pres-
sure waves from the aorta and distal microcirculatory wave
reflections is established; that is, a wave-free period begin-
ning just after the onset of diastole. Importantly, during the
wave-free period, the calculated coronary microcirculatory
resistance is constant and minimal. This insight alone would
not be enough to move their concept forward were it not for
an equally important observation about adenosine. Adeno-
sine has its greatest effect on the systolic component of
resistance, resulting in a significant reduction in the mean
resistance during adenosine-induced hyperemia. This series
of observations logically led the investigators to address 2
key questions. 1) Is the wave-free period resistance similar
or identical to the adenosine-induced reduction in resis-
tance? 2) If so, would the iFR match the FFR?
Sen et al. (12) addressed these questions in a 2-part pilot
study of 157 patients in the cath lab. In answer to the first
question, the investigators found that resistance during the
wave-free period was nearly the same as resistance during
pharmacologic adenosine hyperemia. In the second part, the
investigators compared iFR with FFR in 118 stenoses and
found a very strong (r  0.9) correlation with high (85%)
sensitivity, specificity, and positive and negative predictive
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data, iFR appears comparable to FFR without the need for
pharmacologic vasodilation. Given the barriers to FFR
adoption, the implications for an easier, adenosine-
independent lesion assessment tool are obvious.
Like all new science, we need to look more closely at the
intricacies and possible limitations of iFR. The identifica-
tion of the wave-free period is derived from the complex
wave–intensity analysis as used in previous studies (13). The
wave-free period began 25% of the way into diastole (its
beginning denoted by the dicrotic notch) and ended 5 ms
before the end of diastole (approximately 75% of the
diastolic period). The algorithm for the beat-to-beat calcu-
lation must account for varying R-R intervals of arrhyth-
mias. Indeed, an example of such a problem is shown in the
paper. Although the correlation of iFR with FFR was very
strong with very small mean differences (0.05  0.19),
there were some measurements that varied 10%. Might
the variation be due to the individual’s responsiveness to
adenosine itself, a factor not in play for iFR? It is interesting
that the intrinsic variability of FFR (5%) and iFR (2%)
differed only slightly but favored iFR. Or could the wave-
free period resistances vary due to hemodynamic factors yet
to be tested? Although provocative, these concerns are
tempered by the appreciation that the coefficients of varia-
tion of 2 resistance measurements were in fact identical.
How should iFR be validated for ischemia? In the study
of human coronary physiology, a true clinical gold standard
of ischemia is difficult, if not impossible, to be easily
identified, let alone tested. In the landmark 1996 FFR
validation study reported in the New England Journal of
Medicine, Pijls et al. (4) used a model of 3 outpatient
ischemia stress tests in the same patient and required at least
1 of the 3 tests to convert from positive to negative after PCI
to indicate that the lesion was ischemia related. This
validation protocol has never been repeated and likely never
will. The highly variable false-negative and -positive rates of
different stress test modalities used in subsequent studies
account for currently accepted FFR values wherein a posi-
tive ischemic FFR is 0.75 and a negative ischemic FFR is
0.80, with a zone of mixed results (uncertainly) between
them. Recent clinical outcome studies used 0.80 as a
dichotomous cut point to test treatment strategies (6,7,14).
Although the iFR value of 0.83 provided optimal agree-
ment with an FFR of 0.80, it is unlikely that the same
arduous “3-test” ischemia standard could be repeated for
iFR or any lesion assessment index (e.g., intravascular
ultrasound minimal lumen area). Given the very strong
initial correlation, FFR alone could act as the standard
against which iFR could be tested in a larger population.
Critical to the acceptance of iFR is knowing whether the
wave-free resistance is truly constant and minimal during
hemodynamic perturbations including pharmacologically or
even exercise-induced hyperemia. Like FFR, it remains to
be seen whether a correction for elevated right heart
pressure will improve accuracy and is at all necessary formost coronary artery disease patients. Should hyperemic
wave-free resistance be significantly different under chang-
ing hemodynamic states, the close approximation of iFR to
FFR would need to be reconsidered.
Finally, just as was done with FFR, there will be
numerous clinical conditions, such as assessment of diffuse
disease, serial lesions, severe left ventricular hypertrophy,
and acute coronary syndromes, that will require study of the
iFR behavior. One immediately relevant scenario is that of
serial lesion assessment. FFR cannot assess individual le-
sions in the series without hyperemia and a distal coronary
occlusion pressure, a highly impractical approach. Because it
does not require hyperemia, iFR may be useful to examine
individual serial lesions including those involving the left main
coronary artery, a clinical scenario yet to be tested. We should
also remember that iFR will be subject to all the technical
limitations of FFR regarding pressure-measurement tech-
niques involving guide catheter placement, zero and equilibra-
tion, and identification of signal damping and drift.
The iFR concept has great appeal. It would make lesion
assessment quicker, easier, less expensive, and more widely
used, but it must be carefully vetted before wholesale
implementation. Each new paradigm rewrites the history of
its predecessor. Old theories are discarded and then recon-
structed, emerging under a new paradigm. Such was the
case with FFR compared with earlier physiology methods.
Should large-scale validation studies meet positive expecta-
tions, iFR may take its place among cath lab lesion assess-
ment methods, providing critical information for the treat-
ment of our PCI patients.
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